Insulin Lispro-aabc + Insulin Glargine
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Apr 18, 2024 → Sep 2, 2025
NCT ID
NCT06370715About Insulin Lispro-aabc + Insulin Glargine
Insulin Lispro-aabc + Insulin Glargine is a approved stage product being developed by Cipla for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT06370715. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06370715 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2